A series of new κ opioid receptor (KOR) agonists were developed from the lead compound 4-dimethylamino-1-pentanoylpiperidine (3), a matrine-type alkaloid. Derivatives of 3 were synthesized with a variety of phenyl substituents and evaluated for their antinociceptive effects. Additionally, their selectivity for an opioid receptor was investigated for cis-4c and d, and trans-4g, all of which had high activity exerted through the KOR.

Download full-text PDF

Source
http://dx.doi.org/10.1248/cpb.c15-00963DOI Listing

Publication Analysis

Top Keywords

opioid receptor
12
phenyl substituents
8
development opioid
4
receptor agonists
4
agonists focusing
4
focusing phenyl
4
substituents 4-dimethylamino-3-phenylpiperidine
4
4-dimethylamino-3-phenylpiperidine derivatives
4
derivatives structure-activity
4
structure-activity relationship
4

Similar Publications

Buprenorphine: An anesthesia-centric review.

J Opioid Manag

January 2024

Harvard Medical School; MGH/Harvard Center for Addiction Medicine, Massachusetts General Hospital; Addiction Leadership, Charlestown Community Health Care Center for Pain Management; HOME BASE Veterans and Family Care, Boston, Massachusetts.

Buprenorphine was synthesized in the 1960s as a result of a search for a safe and effective opioid analgesic. Present formulations of buprenorphine are approved for the treatment of both acute and chronic pain. Its long duration of action, high affinity, and partial agonism at the µ-opioid receptor have established it as a mainstay treatment for opioid use disorder (OUD).

View Article and Find Full Text PDF

Objective: Tapentadol causes fewer gastrointestinal adverse events than other potent opioid analgesics because of its low affinity for opioid receptors; however, development of symptoms related to central nervous system disorders, including delirium, has not been well-studied. This study aimed to identify the factors that influence the development of delirium after initiation of tapentadol therapy in hospitalized patients with cancer.

Design: Retrospective study.

View Article and Find Full Text PDF

Molecular mechanisms of inverse agonism via κ-opioid receptor-G protein complexes.

Nat Chem Biol

January 2025

The Bridge Institute, Michelson Center for Convergent Biosciences, University of Southern California, Los Angeles, CA, USA.

Opioid receptors, a subfamily of G protein-coupled receptors (GPCRs), are key therapeutic targets. In the canonical GPCR activation model, agonist binding is required for receptor-G protein complex formation, while antagonists prevent G protein coupling. However, many GPCRs exhibit basal activity, allowing G protein association without an agonist.

View Article and Find Full Text PDF

Safety and Efficacy of opioid-sparing Anesthesia Compared with Traditional opioid-anesthesia: A Scoping Review.

Clin J Pain

November 2024

Department of Anaesthesiology, Critical Care and Pain Medicine, Policlinico Umberto I, Sapienza University of Rome, 00185 Rome, Italy.

Objectives: The rationale of adoption opioid sparing anesthesia (OSA) is to achieve perioperative analgesia with a minimal amount of opioid combined to non-opioid adjuvants during and after surgery, namely multimodal anesthesia. The OSA approach was originally developed to overcome the known complications of opioid-based anesthesia (OA) and the present scoping review (ScR) aims at providing the clinical evidence of safety and efficacy of OSA with respect to OA.

Methods: This ScR is mainly focused on studies presenting evidence on the safety and efficacy of OSA versus OA.

View Article and Find Full Text PDF

Selective Mu-Opioid Receptor Imaging Using F-Labeled Carfentanils.

J Med Chem

January 2025

Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, United States.

Carfentanil, a highly potent synthetic opioid, paradoxically serves as a crucial positron emission tomography (PET) imaging tool in neurobiological studies of the mu-opioid receptor (MOR) system when labeled with carbon-11 ([C]CFN). However, its clinical research use is hindered by extreme potency and the limited availability of short-lived carbon-11 ( = 20.4 min).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!